Risk StewardRisk Steward
NOTES ON HEALTH, MONEY & A CHANGING WORLDPERSONAL PERSPECTIVES · MALAYSIA

A JOURNAL OF PERSPECTIVE

A changing world.
A judgement
of your own.

Progress gives us possibilities.
Perspective helps us choose.

Notes on health, money and the future—exploring what is changing, what we may have overlooked, and what it could mean for our lives.

TURN THE PERSPECTIVE

If we can detect more, what should we do differently?
Beh Risk Steward THE PERSON BEHIND THE PERSPECTIVE ↗

In focus

Fresh questions. Considered perspectives.

A NOTE FROM THE EDITOR

“I’m interested in a brighter future.
And the questions that help us prepare for it.”

Hope and preparation belong in the same conversation. This journal makes room for both.

A little more about Risk Steward ↗
Journal / Perspective

Technology & Society

AI Is Giving Scientists More Time to Discover. That Gives Us Reason to Hope.

AI can help us finish an email. I am rather more interested in whether it can help scientists understand a disease. AlphaGenome Atlas offers an encouraging glimpse of that possibility—and a useful reminder to ask what each breakthrough actually changes.

Scientist examining a sample beside a genetics research display
AI-generated editorial illustration; not a photograph of the Atlas research team.

A better map. A more focused search.

In September 2026, Google DeepMind introduced AlphaGenome Atlas, a resource containing predictions for around 9 billion possible single-letter changes in human DNA. It helps researchers identify which changes may matter most and investigate their potential effects. These are predictions to guide research—not nine billion completed experiments. [1]

Imagine searching for the cause of a rare condition among thousands of possible genetic changes. A tool that helps narrow the list can direct precious time, expertise and laboratory resources towards the most promising leads.

There are already encouraging examples. Google reports that Broad Institute researchers used Atlas to highlight a previously overlooked variant affecting the DNM1 gene. Experiments then supported the predicted disruption. In a separate analysis involving more than 54,000 UK Biobank participants, a researcher identified 22% more non-coding genetic associations using predictions to group variants. [2]

That does not mean 22% more cures. It means researchers found additional clues—and clues are where better understanding begins. The reports do not establish a universal number of hours or years saved by Atlas.

AlphaGenome Atlas: a bigger map for discovery

9 billion
possible single-letter DNA changes with predicted effects

54,000+
UK Biobank participants in one reported analysis

+22%
non-coding genetic associations identified in that analysis

More research clues—not 22% more cures. AI predictions help prioritise variants. Laboratory validation and clinical research remain essential. These reports do not quantify a universal time saving.

Source: Google DeepMind, 8 September 2026. Reported research applications, not demonstrated treatment outcomes.

My view: a better map still needs a route to care

What makes me optimistic is the possibility of moving from a difficult question to a useful lead more efficiently. A better map can help scientists choose where to look. It cannot tell a family that a treatment will be ready by next Tuesday.

A discovery still has to become a treatment that works safely in people. Laboratory research, clinical studies and regulatory review remain essential. [3]

For me, this challenges an easy assumption: that faster discovery automatically means better outcomes for everyone. I would separate three milestones—finding a clue, demonstrating a treatment benefit, and making that treatment accessible. Progress at one is welcome; it does not settle the others.

As possibilities change, our questions can change too. What evidence would make a new option relevant to us? What would access involve? Which health and family arrangements still need to work while we wait? These are questions to revisit, not reasons to put today’s decisions on hold.

Cures for all diseases remain an ambition, not a forecast. Still, I look forward to a future in which fewer families hear, “There is nothing more we can do.”

I am happy to be optimistic about tomorrow. I just would not give today’s responsibilities the day off.

Sources checked: 1 November 2026. General education and personal commentary, not medical advice.

References

[1] Google DeepMind: AlphaGenome Atlas
[2] Google: Reported research applications
[3] FDA: Drug development process

A QUESTION TO CARRY FORWARD

Original article ↗